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In non-febrile mouse models, high dose acetaminophen administration causes profound
hypothermia. However, this potentially hazardous side-effect has not been confirmed
in non-febrile humans. Thus, we sought to ascertain whether an acute therapeutic
dose (20 mg·kg lean body mass) of acetaminophen would reduce non-febrile human
core temperature in a sub-neutral environment. Ten apparently healthy (normal core
temperature, no musculoskeletal injury, no evidence of acute illness) Caucasian males
participated in a preliminary study (Study 1) to determine plasma acetaminophen
concentration following oral ingestion of 20 mg·kg lean body mass acetaminophen.
Plasma samples (every 20 min up to 2-hours post ingestion) were analyzed via enzyme
linked immunosorbent assay. Thirteen (eight recruited from Study 1) apparently healthy
Caucasian males participated in Study 2, and were passively exposed to 20◦C, 40%
r.h. for 120 min on two occasions in a randomized, repeated measures, crossover
design. In a double blind manner, participants ingested acetaminophen (20 mg·kg lean
body mass) or a placebo (dextrose) immediately prior to entering the environmental
chamber. Rectal temperature, skin temperature, heart rate, and thermal sensation were
monitored continuously and recorded every 10 min. In Study 1, the peak concentration
of acetaminophen (14 ± 4 µg/ml) in plasma arose between 80 and 100 min following
oral ingestion. In Study 2, acetaminophen ingestion reduced the core temperature of all
participants, whereas there was no significant change in core temperature over time in
the placebo trial. Mean core temperature was significantly lower in the acetaminophen
trial compared with that of a placebo (p < 0.05). The peak reduction in core temperature
in the acetaminophen trial was reached at 120 min in six of the thirteen participants, and
ranged from 0.1 to 0.39◦C (average peak reduction from baseline = 0.19 ± 0.09◦C).
There was no significant difference in skin temperature, heart rate, or thermal sensation
between the acetaminophen and placebo trials (p > 0.05). The results indicate oral
acetaminophen reduces core temperature of humans exposed to an environment
beneath the thermal neutral zone. These results suggest that acetaminophen may inhibit
the thermogenic mechanisms required to regulate core temperature during exposure to
sub-neutral environments.
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INTRODUCTION
Acetaminophen (APAP) is a widely used analgesic antipyretic
drug branded as Tylenol R© in North America and Paracetamol
in Europe. It is available over-the-counter in various single-
entity formulations and is commonly prescribed in combination
with various opioids to manage moderate pain. Despite its
well-established validity as an analgesic and antipyretic via
inhibition of cyclooxygenase (COX; Aronoff et al., 2006; Li
et al., 2008), a growing body of evidence also demonstrates a
third, hypothermic action of APAP, namely core temperature
(TC) reduction in the absence of fever. This side effect may be
beneficial for inducing therapeutic hypothermia, but may also
increase rates of accidental hypothermia (via exacerbated TC
reductions in environments beneath thermal neutrality; Foster
et al., 2015). 4◦C reductions in TC have been shown within
rodents following intravenous APAP administration (Li et al.,
2008; Ayoub et al., 2011; Gentry et al., 2015). However, such a
hypothermic TC response following oral ingestion of APAP has
not been confirmed in non-febrile humans, within a controlled
laboratory environment.
Confirming if APAP exhibits a hypothermic action in humans
is pertinent. Firstly, due to the inverse relationship between TC
and neurological outcome after stroke or traumatic brain injury
(Reith et al., 1996), APAP could be used as a cheap, safe, and easily
administered pharmacological method to reduce TC when more
invasive and logistically challenging methods are not available
or appropriate (den Hertog et al., 2009). Indeed, APAP has
been shown to reduce mean TC in non-febrile stroke patients
(Kasner et al., 2002), however, the APAP dose used was small
(650 mg), TC was only averaged across a 24 h period, and there
were no obvious environmental or nutritional controls in place.
Secondly, if APAP reduces the resting TC of healthy humans,
it may be involved in the pathology of accidental hypothermia.
For example, if APAP reduces TC via increasing heat loss or
decreasing heat production, this places individuals who consume
APAP at greater risk of developing hypothermia, especially in
winter months. This is of particular concern to thermoregulatory
vulnerable individuals, i.e., the very young (aged 0–4 years) or
the elderly (age ≥ 65 years), who together contributed ≥85%
of UK hospital admissions in 2014 where hypothermia was the
primary or secondary diagnosis (HSCIC, 2015). As APAP is
the most frequently administered over-the-counter medication
worldwide (Blieden et al., 2014), any hypothermic action could
have deleterious implications for a significant number of people,
as outlined above.
The aim of the present study was to determine whether acute,
oral APAP ingestion alters thermoregulatory control during
passive exposure to a sub neutral environment of 20◦C. It was
hypothesized that APAP would decrease TC without any change
in skin temperature (TSK), thermal sensation or heart rate.
MATERIALS AND METHODS
Ethical Approval
All experimental procedures were approved by the University
of Bedfordshire’s Institute for Sport and Physical Activity
Research Ethics committee (approval code 2012ASEP021), and
they conformed to the standards set by the World Association
Declaration of Helsinki ‘Ethical Principles for Research Involving
Human Subjects’.
Participants
Ten Caucasian males [Age (23 ± 2 years), Height (181 ± 8 cm),
Mass (80 ± 8 kg), body fat (16.1 ± 4)] participated in Study
1. Thirteen Caucasian males [Age (23 ± 1 years), Height
(174 ± 3 cm), Mass (73.6 ± 8 kg), body fat (15.5 ± 4.8%)]
participated in Study 2. Eight participants from Study 1 went
on to participate in Study 2, with two discontinuing their
participation for Study 2 (see Figure 1 for trial profile).
Participants were provided with written information regarding
all experimental procedures, with supporting oral explanations
from the principal investigator. Participants then subsequently
provided written informed consent. The participants were non-
smokers, non-febrile (resting TC < 38◦C), and were free from
musculoskeletal injury.
Inclusion/Exclusion Criteria
Prior to each laboratory visit, participants completed an informed
consent sheet, alcohol use disorder identification test (AUDIT;
Saunders et al., 1993) a breathalyzer test (AlcoSense, One,
Berkshire, UK), and an APAP risk assessment questionnaire. To
avoid the risk of liver damage inflicted by APAP, participants
were not able to participate in the research if they scored above
ten on the AUDIT questionnaire or alcohol was present in their
bloodstream. No participants presented with any pre-existing
medical conditions that may have put them at an increased risk
of APAP toxicity. Due to potential thermoregulatory adaptions
(Gibson et al., 2015), individuals were not permitted to take part
in any experimental procedures if they were heat acclimated or
acclimatized. Thus, those who had traveled to a hot climate or
participated in a laboratory based heat acclimation protocol less
than three weeks prior to the experiment were not permitted to
take part (Garrett et al., 2011). All participants presented with a
stable core temperature (36.5–37.5◦C) and were thus considered
non-febrile.
STUDY 1
Study 1 Design
To identify when the peak plasma concentration of ACT arises
after oral ingestion (20 mg·kg LBM), eight Caucasian males
visited the laboratory on one occasion. Participants adhered
to all experimental controls listed in the “general experimental
controls” section.
Study 1 Controls
On the trial day, APAP (Paracetamol, Aspar Pharmaceuticals,
London, UK) was administered at a dose equal to 20 mg·kg of
lean body mass. Each capsule contained a maximum of 500 mg
of APAP. The dosing range of APAP in the present work was
1019–1420 mg (mean= 1293± 163 mg). This dosing was advised
by a leading clinician and consultant anesthetist, and has been
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FIGURE 1 | Trial profile. APAP, acetaminophen.
used previously (Mauger et al., 2014; Coombs et al., 2015). All
participants arrived at the laboratory having fasted overnight
(from 0000 to arrival). To control the gastric emptying rate
of APAP, participants ingested a standardized meal [cornflakes
(50 g), milk (250 ml) and 1 l of water] 1 h prior to APAP or
placebo ingestion. Experimental trials took place within a custom
built environmental chamber (Custom build, T.I.S.S, Hampshire,
UK) which simulated the desired environmental condition of
20◦C and 40% relative humidity. The participants’ clothing was
standardized across all trials, in which they were barefoot, topless,
and wore knee length shorts.
Study 1 Protocol
Participants arrived at the laboratory at 0830. Upon arrival,
participant’s lean body mass was calculated via air displacement
plethysmography (Bod Pod, 2000A, Birmingham, UK). At
0845 participants consumed a standardized meal (see “Study 1
Controls”). At 0920, participants remained seated and a 20G
cannula (Introcan R© Safety Winged, B Braun Medical, Sheffield,
UK) was placed in a prominent vein within the antecubital
fossa. At 0930, participants entered the environmental chamber
(20◦C, 40% r.h.). At 0945, participants orally ingested APAP
(Paracetamol, Aspar Pharmaceuticals, London, UK). Blood
samples were drawn into a heparin coated EDTA tube
(Vacuette R© , Greiner Bio-One, Stroudwater, UK) immediately
prior to APAP ingestion, and subsequently at 20, 40, 60, 80, 100,
and 120 min post ingestion. Peak plasma levels of APAP were
quantified using a commercially available ELISA kit (Microplate
EIA kit, Alere toxicology, Abingdon, UK) read in duplicate at a
dual wavelength of 450 and 650 nm (Sunrise, Tecan, Seestrasse,
Männedorf). The average inter-plate CV was 5% (intra-plate CV
not applicable due to assay layout). Venous hemoglobin (Hb
201+, Hemocue, Staines, UK) and haematocrit (Haematospin
1300, Hawksley, Sussex, UK) concentrations were taken in
duplicate and averaged at each point of blood sampling. This
data was used to calculate changes in plasma volume according
to the Dill and Costill method (Dill and Costill, 1974), and APAP
concentrations were subsequently adjusted in accordance with
any changes in plasma volume.
STUDY 2
Study 2 Design
To determine the hypothermic effect of APAP, 13 participants
visited the laboratory at the same time of day on two occasions,
each separated by at least 7 day. Both visits were randomized and
double blinded. The trials took place within an environmental
chamber (20◦C, 40% r.h.) set beneath the thermoneutral zone
(i.e., subneutral; Kingma et al., 2014; Schlader, 2015) for 120 min.
A sub-neutral environment was chosen for two reasons, (i) to
ensure that heat loss mechanisms would not become activated
during the protocol and (ii) to help replicate the sub-neutral
conditions in previous animal work concerning APAP induced
hypothermia (Botting and Ayoub, 2005).
Study 2 Controls
On each trial day, APAP (Paracetamol, Aspar Pharmaceuticals,
London, UK) or a placebo (dextrose, MYPROTEIN, Cheshire,
UK) was administered at a dose equal to 20 mg·kg of lean
body mass. Each capsule contained a maximum of 500 mg of
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APAP. The dosing range of APAP in the present work was 1019–
1420 mg (mean = 1226 ± 135 mg). Controls for gastric content,
nutritional intake, environmental conditions, and clothing were
identical to that of Study 1 (see “Study 1 Controls”).
Study 2 Protocol
Participants arrived at the laboratory at 7000 or 1000, where
each participant’s time of arrival was consistent through all
experimental trials to account for any circadian rhythm or
diurnal variations in TC (Waterhouse et al., 2005). Upon
arrival (0700 or 1000), participants were instrumented for the
measurement of TC, TSK, and heart rate (see “Instrumentation
and Equations” for details). Thirty min after arrival (0730 or
1030), participants consumed the standardized breakfast. Sixty
min after the meal was consumed (0830 or 1130), participants
ingested APAP or placebo. Participants remained rested in
an upright-seated position between meal consumption and
APAP or placebo ingestion, and for the duration of data
collection to ensure resting physiological status was attained and
maintained throughout the data collection. Data collection began
immediately after ingestion of APAP or placebo, i.e., 60 min after
meal consumption. Resting measurements of TC, TSK, heart rate,
and thermal sensation were taken 5 min prior to APAP or placebo
ingestion (0825 or 1125), and subsequently every 10 min for
120 min post ingestion.
Study 2 Instrumentation and Equations
Copper based thermocouples (Grant, EUS-U-VS5-0, Dorset, UK)
connected to a wireless data logger (Grant, Squirrel Series, Dorset,
UK) recorded TSK at four sites: calf, thigh, chest, and triceps
(Bruning et al., 2013). Thermocouples were securely attached
to the belly of each muscle by hypafix surgical adhesive tape
(BSN medical, D-22771, Hamburg, Germany). The weighted TSK
of four sites was subsequently calculated using the equation
(Ramanathan, 1964) below:
TSK = 0.3 ∗ (Tarm + Tchest)+ 0.2 ∗ (Tcalf + Tthigh)
TC was measured via insertion of a rectal thermistor (Henleys,
400H/4491H, Hertfordshire, UK) 10 cm beyond the anal
sphincter. The thermistor was connected via cable to a portable
data logger (Libra Medical, ET402, Birmingham, UK), in which
TC was continuously displayed throughout each experimental
protocol.
Thermal sensation (Young et al., 1987) was obtained using
a 0–8 scale ranging from unbearably cold (0) to unbearably
hot (8). Heart rate was measured during all tests using short-
range telemetry. A Polar heart rate transmitter belt (Polar, FS1,
Birmingham, UK), coated with conductive gel to enhance signal
detection, was strapped to the participant’s chest. Heart rate
was displayed on a corresponding Polar watch (Polar, FS1,
Birmingham, UK).
Statistical Analysis
Statistical analyses were performed using IBM SPSS statistics
version 21 (SPSS Inc., Chicago, IL, USA). Power analyses
were conducted with GPower software version 3.1 (Heinrich
University, Düsseldorf, Germany). Utilizing TC data from a
previous experiment where APAP was tested as a hypothermic
agent (Dippel et al., 2003a), it was determined that a total of
13 participants were required to achieve a statistical power of
90%. Statistical assumptions were checked using conventional
graphical methods (quantile–quantile plots, histograms; Grafen
and Hails, 2002) and were deemed plausible. Central tendency
and dispersion are reported as means ± SD. Mean differences
in TC, TSK, heart rate, and thermal sensation between APAP
and placebo were measured using a two-way analysis of variance
(ANOVA). In the event of a significant F statistic for the main
effects or interaction effects, a Sidak post hoc adjustment was
performed, and 95% confidence intervals (CI) are presented
where appropriate. The two-tailed alpha level of significance
testing was set as p < 0.05.
RESULTS
Study 1
The peak plasma concentration of APAP during the 120 min
experiment was 14 ± 4 µg/ml (range, 8–19 µg/ml). The time
for APAP to reach maximal concentrations was 96 ± 13 min
(range, 80–100 min). Figure 2 displays the plasma concentration
response of APAP, every 20 min for 2 h.
Study 2
TC
Main effects were found for condition (F1,1 = 28.68,
p < 0.001), and time (F1,12 = 17.23, p < 0.001) between
APAP (36.73 ± 0.1◦C; 95% CI = 36.67–36.8◦C) and placebo
(36.83 ± 0.1◦C; 95% CI = 36.77–36.89◦C). A significant
interaction effect was also found (F1,12 = 51.68, p < 0.001),
revealing that mean TC was significantly lower in the APAP
group from 30 min to the cessation of the trial. The peak TC
FIGURE 2 | Mean ± standard deviation values for plasma APAP
concentration response to oral intake of 20 mg·kg lean body mass-1
APAP during a resting two-hour period.
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reduction from baseline arose 110 min (six subjects) or 120 min
(seven subjects) after ingestion, and ranged from 0.1–0.39◦C
(mean = 0.19 ± 0.09◦C). The TC response to APAP ingestion
is displayed in Figure 3. Individual responses to APAP are also
shown in Figure 4.
TSK
There were no significant main effects for condition (F1,1 = 0.01,
p > 0.05) between APAP (26.8 ± 1.3◦C; 95% CI = 26–27.6◦C)
and placebo (26.9 ± 0.8◦C; 95% CI = 26.41–27.3◦C), but there
was a main effect for time (F1,12 = 30.46, p < 0.001). No
interaction effects were found (F1,12 = 0.39, p > 0.05).
Thermal Sensation
There were no significant main effects for condition (F1,1 = 0.37,
p > 0.05) between APAP (3.4 ± 0.2; 95% CI = 3.4–3.5) and
placebo (3.4± 0.2; 95% CI= 3.3–3.5), but there was a main effect
for time (F1,12 = 17.76, p < 0.001). No interaction effects were
found (F1,12 = 0.341, p > 0.05).
Heart Rate
There were no significant main effects for condition
(F1,1 = 0.76, p > 0.05) between APAP (62 ± 8 b·min−1;
95% CI = 58–66 b·min−1) and placebo (63 ± 7 b·min−1; 95%
CI = 60–66 b·min−1), but there was a main effect for time
(F1,12 = 5.57, p < 0.001). No interaction effects were found
(F1,12 = 0.24, p > 0.05).
DISCUSSION
Study 1 determined that APAP peak plasma concentration,
following oral administration at 20 mg·kg of lean body mass,
was 14 ± 4 µg/ml, with maximal concentrations reached
96 ± 13 min (range, 80–100 min; Figure 2) post ingestion.
Study 2 demonstrated, in line with the stated hypothesis, that
FIGURE 3 | Mean ± standard deviation values for core temperature
(TC) in both the APAP and placebo conditions. ∗Significant main effect for
condition. #Significant main effect for time. †Significant interaction effect.
FIGURE 4 | Individual core temperature (TC) responses in the placebo
(A) and APAP condition (B).
oral APAP ingestion, at the same dose as Study 1, elicited a
notable hypothermic action in non-febrile humans. On average,
TC was 0.14◦C lower during the 120 min exposure to 20◦C in
the APAP condition compared with a placebo. The maximum
(peak) reduction in TC in the APAP condition was 0.19± 0.09◦C
(range = 0.1–0.39◦C). Having ingested APAP, all participants
displayed a gradual decrease in TC, and in seven participants,
this did not plateau in the 120 min study period (Figure 4).
However, due to the relatively short experiment time, the notion
that TC began to recover before the end of the 120 min
period in the remaining six participants is speculative. To our
knowledge, this is the first study that accurately demonstrates oral
APAP ingestion to reduce non-febrile human TC in sub neutral
conditions (i.e., beneath thermal neutrality) within apparently
healthy human participants (Figure 3).
The effect of APAP on non-febrile temperature regulation
has been investigated previously in mice (Ayoub et al., 2004;
Li et al., 2008; Ayoub et al., 2011; Gentry et al., 2015) and
humans (Kasner et al., 2002; Dippel et al., 2003b; den Hertog
et al., 2009). There are also reports of severe hypothermia
(TC = 28◦C on hospital admission) following acute APAP
overdose (Rollstin and Seifert, 2012). Prior to the present work,
this potentially hazardous side-effect had not been confirmed
in passive, nutritionally controlled participants or conducted
in a temperature controlled environmental chamber. Despite a
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significant interaction effect (condition∗time) for TC, the 120 min
trial period did not consistently allow for a plateau in TC to
be demonstrated, i.e., the maximum TC reduction in seven of
the thirteen participants was not seen prior to the final time
point of 120 min (Figure 4). Although TC seemed to plateau
in six participants, a longer experimental duration is required
to reliably determine when TC will begin to recover to normal
(i.e., pre APAP ingestion) values after administration of APAP.
However, given that the cellular target of APAP for inducing
hypothermia is not known in humans, it is difficult to predict if
the peak reduction in TC is line with the peak plasma or cerebral
spinal fluid (CSF) concentrations.
Due to its worldwide use, the pharmacokinetics of APAP
has been investigated extensively. However, it was important to
determine the short-term concentration response in the present
experiment (Study 1) as this has not been analyzed (i) following
doses of 20 mg·kg of lean body mass and (ii) following the
implemented nutritional controls. The data presented here is;
however, in line with previous work. Early work using gas
chromatography demonstrated that in adult humans (fasted and
apparently healthy), oral doses of 1000 and 2000 mg APAP reach
peak plasma concentrations in ∼60 and 120 min, respectively
(Rawlins et al., 1977). An oral dose relative to lean body mass
was used in the present experiment because the volume of
distribution of hydrophilic drugs correlates more strongly with
lean body mass compared with total body mass (Morgan and
Bray, 1994). Consequently, the doses administered here ranged
from 1019 to 1415 mg (mean= 1226± 135 mg). Thus, modeling
previous pharmacokinetic data (Rawlins et al., 1977) and that
from Study 1, it can be predicted that during Study 2, peak
plasma concentrations were reached within the study period of
120 min. However, given that TC did not consistently recover in
the 120 min study period (Figure 4), this raises the notion that
the peak reduction in TC is more likely to be in line with peak
CSF concentrations of APAP, which may take 4 hours to arise
after an acute 1000 mg dose (Singla et al., 2012). Future work
should elucidate when TC begins to recover after acute APAP
exposure, as this may have important implications if APAP is to
be used as a hypothermic agent following brain injury (Saxena
et al., 2015). It would also be beneficial to ascertain if the maximal
TC reductions are in line with peak CSF concentrations, as this
would help identify if APAP induced hypothermia is mediated
within the central nervous system.
In the UK, cold-related mortality presently accounts for at
least one order of magnitude more deaths than heat-related
mortality (around 61 and 3 deaths per 100,000 population per
year, respectively; Vardoulakis et al., 2014). Consequently, in 2014
there were over 16,000 hospital admissions in the UK whereby
hypothermia was the primary or secondary cause (HSCIC, 2015).
Exposure to environments beneath thermoneutrality clearly
present a major health risk, particularly in thermoregulatory
vulnerable populations such as the very young and the elderly,
who account for more than 85% of these admissions. The
primary deleterious effects of cold on the human body arise
when TC falls below 35◦C, although the autonomic physiological
responses required to maintain TC (tachycardia and shivering)
can increase cardiovascular strain and can lead to secondary
events [particularly in elderly individuals (Parsons, 2014)]. The
data obtained in this experiment demonstrates that TC is not
as efficiently defended when participants ingest APAP in a
subneutral environment. This is particularly concerning as the
average thermal sensation in both groups (APAP and placebo)
was 3.4 ± 2 (3.5 = “comfortable”), and no participants reported
feeling “cold” on the thermal sensation scale. If APAP inhibited
normal thermogenic mechanisms in these conditions, it is
likely that these TC reductions will be exacerbated in colder
environments. More work is needed in this area to confirm
when the peak reduction in TC arises, and the variability in this
response. Moreover, it is unclear if APAP induced hypothermia is
exacerbated in cold conditions (where there is a greater reliance
on thermogenesis), which may be inhibited in the presence of
a COX inhibitor (such as APAP). This specific hypothesis has
recently been proposed by our group (Foster et al., 2015), and
should be investigated in future work. These findings could have
implications for public health recommendations.
The molecular target for APAP induced hypothermia in
humans is not well established, but is likely due to inhibition
of the COX enzyme. When administered orally (1000 mg),
APAP is a potent inhibitor of COX-2 in intact cells, but may
also inhibit COX-1 (Hinz et al., 2008). Given that participants
in this study were exposed to sub-neutral environmental
temperatures, it is possible that COX may have been prevented
from activating thermogenic responses to this environment
(Foster et al., 2015). Although the role of COX in non-
febrile thermogenesis remains a topic of debate (Aronoff and
Romanovsky, 2007; Foster et al., 2015), recent evidence supports
a role for COX in this capacity. For example, it has been
demonstrated that COX-2 is essential for UCP-1 induction
in beige/brite adipocytes during cold exposure; TC was not
efficiently defended during acute cold exposure in COX-2
gene deficient mice compared with their wild-type counterparts
(Madsen et al., 2010). More recently, intravenous parecoxib
(COX-2 selective inhibitor) administration significantly reduced
post-operative shivering in non-febrile patients (Li et al.,
2014; Shen et al., 2015). Thus, it is possible that during
sub neutral conditions, a reduction in autonomic shivering
responses (mediated by APAP induced COX-2 inhibition) could
contribute to the decline in TC witnessed in the present work
(Figure 3).
CONCLUSION
It has been demonstrated that acute APAP ingestion at a dose
of 20 mg·kg lean body mass reduces non-febrile TC during
a 120 min passive exposure to 20◦C, 40% r.h (Figure 3).
Future research should seek to determine if APAP reduces the
capacity of the thermoregulatory system to maintain TC during
cold exposure. Moreover, it should be determined if the peak
reductions in TC are in line with peak CSF concentrations. Such
findings would determine (i) if APAP induced hypothermia is
mediated through a brain derived mechanism and (ii) if these
TC reductions have implications for the pathology of accidental
hypothermia.
Frontiers in Pharmacology | www.frontiersin.org 6 March 2016 | Volume 7 | Article 54
fphar-07-00054 April 5, 2016 Time: 17:5 # 7
Foster et al. Acetaminophen Alters Non-febrile Thermoregulation
AUTHOR CONTRIBUTIONS
JF, LT, and AM contributed to the study design, data
interpretation and manuscript revision. JF, KT, and SW
contributed to data collection and also contributed to manuscript
revision. All aspects of the project were supervised by LT, and
AM. All authors approved the final version of the manuscript and
all authors qualifying for authorship are listed.
ACKNOWLEDGMENTS
The authors would like to thank Warwick Riley, Principle
Laboratory Technician, University of Bedfordshire, for his
technical assistance with the environmental chamber. The
authors also thank Dr. Loukia Tsaprouni for technical assistance
with the ELISA assay. Finally, the authors are especially
appreciative of all those who participated in the experiment.
REFERENCES
Aronoff, D., Oates, J., and Boutaud, O. (2006). New insights into the mechanism
of action of acetaminophen: its clinical pharmacologic characteristics reflect its
inhibition of the two prostaglandin H2 synthases. Clin. Pharmacol. Ther. 79,
9–19. doi: 10.1016/j.clpt.2005.09.009
Aronoff, D. M., and Romanovsky, A. A. (2007). Eicosanoids in non-
febrile thermoregulation. Prog. Brain Res. 162, 15–25. doi: 10.1016/s0079-
6123(06)62002-5
Ayoub, S., Pryce, G., Seed, M., Bolton, C., Flower, R., and Baker, D. (2011).
Paracetamol-induced hypothermia is independent of cannabinoids and
transient receptor potential vanilloid-1 and is not mediated by AM404. Drug
Metab. Dispos. 39, 1689–1695. doi: 10.1124/dmd.111.038638
Ayoub, S. S., Botting, R. M., Goorha, S., Colville-Nash, P. R., Willoughby, D. A., and
Ballou, L. R. (2004). Acetaminophen-induced hypothermia in mice is mediated
by a prostaglandin endoperoxide synthase 1 gene-derived protein. Proc. Natl.
Acad. Sci. U.S.A. 101, 11165–11169. doi: 10.1073/pnas.0404185101
Blieden, M., Paramore, L. C., Shah, D., and Ben-Joseph, R. (2014). A perspective
on the epidemiology of acetaminophen exposure and toxicity in the United
States. Expert Rev. Clin. Pharmacol. 7, 341–348. doi: 10.1586/17512433.2014.
904744
Botting, R., and Ayoub, S. S. (2005). COX-3 and the mechanism of action of
paracetamol/acetaminophen. Prostaglandins Leukot. Essent. Fatty Acids 72,
85–87. doi: 10.1016/j.plefa.2004.10.005
Bruning, R., Dahmus, J., Kenney, W. L., and Alexander, L. (2013). Aspirin and
clopidogrel alter core temperature and skin blood flow during heat stress. Med.
Sci. Sports Exerc. 45, 674–682. doi: 10.1249/MSS.0b013e31827981dc
Coombs, G., Cramer, M., Ravanelli, N., Morris, N., and Jay, O. (2015). Does
acetaminophen alter core temperature and sweating during exercise in hot-
humid conditions? Scand. J. Med. Sci. Sports 25, 96–103. doi: 10.1111/sms.12336
den Hertog, H. M., Van Der Worp, H. B., Van Gemert, H. M. A., Algra, A.,
Kappelle, L. J., Van Gijn, J., et al. (2009). The Paracetamol (Acetaminophen)
In Stroke (PAIS) trial: a multicentre, randomised, placebo-controlled, phase III
trial. Lancet Neurol. 8, 434–440. doi: 10.1016/s1474-4422(09)70051-1
Dill, D. B., and Costill, D. L. (1974). Calculation of percentage changes in volumes
of blood, plasma, and red cells in dehydration. J. Appl. Physiol. 37, 247–248.
Dippel, D. W., Van Breda, E. J., Van Der Worp, H. B., Van Gemert, H. M., Kappelle,
L. J., Algra, A., et al. (2003a). Timing of the effect of acetaminophen on body
temperature in patients with acute ischemic stroke. Neurology 61, 677–679. doi:
10.1212/01.WNL.0000080364.40229.0B
Dippel, D. W., Van Breda, E. J., Van Der Worp, H. B., Van Gemert, H. M. A., Meijer,
R. J., Kappelle, L. J., et al. (2003b). Effect of paracetamol (acetaminophen)
and ibuprofen on body temperature in acute ischemic stroke PISA, a phase II
double-blind, randomized, placebo-controlled trial [ISRCTN98608690]. BMC
Cardiovasc. Disord. 3:2. doi: 10.1186/1471-2261-3-2
Foster, J., Mauger, A. R., Chrismas, B. C., Thomasson, K., and Taylor, L.
(2015). Is prostaglandin E (PGE) involved in the thermogenic response to
environmental cooling in healthy humans? Med. Hypotheses 85, 607–611. doi:
10.1016/j.mehy.2015.07.022
Garrett, A. T., Rehrer, N. J., and Patterson, M. J. (2011). Induction and decay of
short-term heat acclimation in moderately and highly trained athletes. Sports
Med. 41, 757–771. doi: 10.2165/11587320-000000000-00000
Gentry, C., Andersson, D. A., and Bevan, S. (2015). TRPA1 mediates
the hypothermic action of acetaminophen. Sci. Rep. 5, 12771. doi:
10.1038/srep12771
Gibson, O. R., Mee, J. A., Tuttle, J. A., Taylor, L., Watt, P. W., and Maxwell, N. S.
(2015). Isothermic and fixed intensity heat acclimation methods induce similar
heat adaptation following short and long-term timescales. J. Therm. Biol. 4,
55–65. doi: 10.1016/j.jtherbio.2015.02.005
Grafen, G., and Hails, R. (2002). Modern Statistics for Life Sciences. New York, NY:
Oxford University Press.
Hinz, B., Cheremina, O., and Brune, K. (2008). Acetaminophen (paracetamol)
is a selective cyclooxygenase-2 inhibitor in man. FASEB J. 22, 383–390. doi:
10.1096/fj.07-8506com
HSCIC (2015). Hospital Episode Statistics: Admitted Patient Care 2013 to 2014.
Leeds: Health and Social Care Information Centre. Available at: http://www.
hscic.gov.uk/media/15004/Hypothermia-national-stats-by-age-2005-06-to-20
13-14/xls/Hypothermia_national_stats_by_age_200506_to_201314.xlsx
Kasner, S. E., Wein, T., Piriyawat, P., Villar-Cordova, C. E., Chalela, J. A.,
Krieger, D. W., et al. (2002). Acetaminophen for altering body temperature
in acute stroke: a randomized clinical trial. Stroke 33, 130–134. doi:
10.1161/hs0102.101477
Kingma, B. R., Frijns, A. J., Schellen, L., and Van Marken Lichtenbelt, W. D.
(2014). Beyond the classic thermoneutral zone: including thermal comfort.
Temperature 1, 142–149. doi: 10.4161/temp.29702
Li, S., Dou, W., Tang, Y., Goorha, S., Ballou, L. R., and Blatteis, C. M. (2008).
Acetaminophen: antipyretic or hypothermic in mice? In either case, PGHS-
1b (COX-3) is irrelevant. Prostaglandins Other Lipid Mediat. 85, 89–99. doi:
10.1016/j.prostaglandins.2007.10.007
Li, X., Zhou, M., Xia, Q., Li, W., and Zhang, Y. (2014). Effect of parecoxib sodium
on postoperative shivering: a randomised, double-blind clinical trial. Eur. J.
Anaesthesiol. 31, 225–230. doi: 10.1097/01.EJA.0000436684.94403.1e
Madsen, L., Pedersen, L. M., Lillefosse, H. H., Fjaere, E., Bronstad, I., Hao, Q.,
et al. (2010). UCP1 induction during recruitment of brown adipocytes in white
adipose tissue is dependent on cyclooxygenase activity. PLoS ONE 5:e11391.
doi: 10.1371/journal.pone.0011391
Mauger, A. R., Taylor, L., Harding, C., Wright, B., Foster, J., and Castle, P.
(2014). Acute acetaminophen (paracetamol) ingestion improves time to
exhaustion during exercise in the heat. Exp. Physiol. 99, 164–171. doi:
10.1113/expphysiol.2013.075275
Morgan, D. J., and Bray, K. M. (1994). Lean body mass as a predictor of drug
dosage. Implications for drug therapy. Clin. Pharmacokinet. 26, 292–307. doi:
10.2165/00003088-199426040-00005
Parsons, K. (2014). Human Thermal Environments: The Effects of Hot, Moderate,
and Cold Environments on Human Health, Comfort, and Performance. London:
CRC Press.
Ramanathan, N. L. (1964). A new weighting system for mean surface temperature
of the human body. J. Appl. Physiol. 19, 531–533.
Rawlins, M. D., Henderson, D. B., and Hijab, A. R. (1977). Pharmacokinetics of
paracetamol (acetaminophen) after intravenous and oral-administration. Eur.
J. Clin. Pharmacol. 11, 283–286. doi: 10.1007/bf00607678
Reith, J., Jorgensen, H., Pedersen, P., Nakamaya, H., Jeppesen, L., Olsen, T.,
et al. (1996). Body temperature in acute stroke: relation to stroke severity,
infarct size, mortality, and outcome. Lancet 347, 422–425. doi: 10.1016/S0140-
6736(96)90008-2
Rollstin, A., and Seifert, S. A. (2012). Acetaminophen overdose in profound
hypothermia. Clin. Toxicol. 50, 589–589.
Saunders, J. B., Aasland, O. G., Babor, T. F., De La Fuente, J. R., and
Grant, M. (1993). Development of the alcohol use disorders identification
test (AUDIT). WHO collaborative project on early detection of persons with
harmful alcohol consumption-II. Addiction 88, 791–791. doi: 10.1111/j.1360-
0443.1993.tb02093.x
Saxena, M., Young, P., Pilcher, D., Bailey, M., Harrison, D., Bellomo, R., et al.
(2015). Early temperature and mortality in critically ill patients with acute
Frontiers in Pharmacology | www.frontiersin.org 7 March 2016 | Volume 7 | Article 54
fphar-07-00054 April 5, 2016 Time: 17:5 # 8
Foster et al. Acetaminophen Alters Non-febrile Thermoregulation
neurological diseases: trauma and stroke differ from infection. Intensive Care
Med. 41, 823–832. doi: 10.1007/s00134-015-3676-6
Schlader, Z. J. (2015). The human thermoneutral and thermal comfort zones:
thermal comfort in your own skin blood flow. Temperature 2, 47–48. doi:
10.4161/23328940.2014.983010
Shen, H., Chen, Y., Lu, K. Z., and Chen, J. (2015). Parecoxib for the
prevention of shivering after general anesthesia. J. Surg. Res. 197, 139–144. doi:
10.1016/j.jss.2015.03.011
Singla, N. K., Parulan, C., Samson, R., Hutchinson, J., Bushnell, R., Beja, E. G.,
et al. (2012). Plasma and cerebrospinal fluid pharmacokinetic parameters after
single-dose administration of intravenous, oral, or rectal acetaminophen. Pain
Pract. 12, 523–532. doi: 10.1111/j.1533-2500.2012.00556.x
Vardoulakis, S., Dear, K., Hajat, S., Heaviside, C., Eggen, B., and Mcmichael, A. J.
(2014). Comparative assessment of the effects of climate change on heat-and
cold-related mortality in the United Kingdom and Australia. Environ. Health
Perspect. 122, 1285–1292. doi: 10.1289/ehp.1307524
Waterhouse, J., Drust, B., Weinert, D., Edwards, B., Gregson, W., Atkinson, G.,
et al. (2005). The circadian rhythm of core temperature: origin and some
implications for exercise performance. Chronobiol. Int. 22, 207–225. doi:
10.1081/CBI-200053477
Young, A. J., Sawka, M. N., Epstein, Y., Decristofano, B., and Pandolf, K. B. (1987).
Cooling different body surfaces during upper and lower-body exercise. J. Appl.
Physiol. 63, 1218–1223.
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Foster, Mauger, Thomasson, White and Taylor.
This is an open-access article distributed under the terms of the
Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original
author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these
terms.
.
Frontiers in Pharmacology | www.frontiersin.org 8 March 2016 | Volume 7 | Article 54
